Hamburg, Germany | Oxfordshire, UK | Cambridge, MA, USA – In a significant development for the field of drug discovery, Evotec OAI AG (Deutsche Börse: EVT, TecDAX 30), a leading global provider of integrated, high-value-added drug discovery and development services, has announced a new collaboration with Nuvios, Inc. This partnership aims to explore novel small molecule compounds with potential therapeutic applications, particularly for osteoporosis treatment and prevention.
The Collaboration: A Leap Forward in Osteoporosis Treatment
The collaboration between Evotec OAI and Nuvios focuseshttp://nuvios on the innovative screening of small molecule compounds using Evotec OAI’s state-of-the-art ultra high-throughput screening (uHTS) technology. This technology includes proprietary, confocal fluorescence techniques, alongside other advanced methodologies, to rapidly identify biologically active compounds. The primary goal of this partnership is to utilize Nuvios’ proprietary assays to profile the effects of these compounds on the growth and differentiation of osteoclasts and osteoblasts—cells critical to bone formation and resorption.
Osteoporosis, a condition characterized by weakened bones and an increased risk of fractures, is a significant public health concern, especially among the aging population. The collaboration aims to discover novel activators of bone anabolic activity, which could lead to groundbreaking treatments that not only prevent bone loss but also promote bone formation.
A Strategic Alliance: Leveraging Expertise and Technology
Jörn Aldag, President and CEO of Evotec OAI, expressed enthusiasm about the partnership, highlighting its potential to leverage recent breakthroughs in the biology and chemistry of anabolic bone formation. “We are delighted to work with Nuvios in this exciting area, and we look forward to applying our skills in assay development and high-throughput screening to help create novel drugs for osteoporosis,” Aldag stated. This collaboration represents a strategic alignment of Evotec OAI’s technological prowess with Nuvios’ innovative approach to drug discovery, promising to accelerate the development of new therapeutic options.
About Evotec OAI AG: A Leader in Drug Discovery and Development
Evotec OAI has built a strong reputation as a premier partner for pharmaceutical and biotechnology companies worldwide, offering a comprehensive suite of drug discovery and development services. The company’s core business strategy emphasizes innovation in drug discovery, underpinned by a robust technology platform that integrates world-class biology and chemistry capabilities.
The company’s service offerings range from assay development and high-throughput screening to compound optimization and drug manufacturing. Additionally, Evotec OAI pursues select discovery programs to develop drug candidates for early out-licensing, further enhancing its value proposition to clients and partners. With a team of over 600 dedicated professionals based in Hamburg, Germany, and Oxfordshire, UK, Evotec OAI continues to drive forward its mission of delivering high-quality solutions to the pharmaceutical industry.
The Future of Nuvios and Evotec OAI: Pioneering Innovation in Healthcare
This collaboration with Nuvios not only reinforces Evotec OAI’s commitment to pioneering innovative healthcare solutions but also exemplifies the transformative potential of combining cutting-edge technology with deep scientific expertise. As the partnership progresses, it holds the promise of significant advancements in the treatment of osteoporosis, potentially benefiting millions of patients worldwide.
The Nuvios revolution, as represented by this partnership, underscores the critical role of collaborative efforts in advancing medical science. By pushing the boundaries of technology and innovation, Nuvios and Evotec OAI are poised to make a lasting impact on the future of healthcare, offering hope for new and improved therapies for osteoporosis and beyond.
4o
